SureTrader
Home > Boards > US Listed > Biotechs >

Organovo Holdings, Inc. (ONVO)

ONVO RSS Feed
Add ONVO Price Alert      Hide Sticky   Hide Intro
Moderator:
Search This Board: 
Last Post: 4/18/2018 3:52:26 PM - Followers: 311 - Board type: Free - Posts Today: 0

WELCOME TO THE ORGANOVO BOARD


 
     Organovo is a three-dimensional biology company focused on delivering breakthrough bioprinting technology and creating tissue on demand for research and medical applications.
The company's NovoGen three-dimensional bioprinting technology is a platform that works across all tissue and cell types.
Organovo's NovoGen MMX Bioprinter was selected as one of the "Best Inventions of 2010" by TIME Magazine.
Organovo is helping pharmaceutical partners develop human biological disease models in three dimensions that enable therapeutic drug discovery and development.
Organovo's bioprinting technology can also be developed to create surgical tissues direct therapy.
Organovo leads the way in solving complex medical research problems and building the future of medicine.

COMPANY PROFILE via YouTube
http://www.youtube.com/watch?feature=player_embedded&v=-A-uH15bQZw

 
ONVO Security Details Share Structure

Shares Outstanding 77,816,787 a/o Mar 16, 2014
Float 50,000,000 a/0 May24,2014
Authorized Shares 150,000,000 a/o May24, 2014


IR and Media Contacts:
Investor Relations Contact: ir@organovo.com
Media Contact: media@organovo.com

Mailing Address:
Organovo, Inc.
6275 Nancy Ridge Drive, Suite 110
San Diego, CA 92121
Phone: 1-858-550-9994


For all the latest company information, details, news, please visit http://www.organovo.com

 
Organovo's Scientific Founder and Chief Scientific Officer, Dr. Gabor Forgacs
is the Executive and Scientific Director of the Shipley Center for Innovation at Clarkson University and the George H. Vineyard Professor of Biological Physics at the University of Missouri.
He developed Organovo's breakthrough organ printing technology while leading a team of top regenerative medicine scientists from multiple universities, with the backing of a $5MM National Science Foundation Grant.
Professor Forgacs is the author of more than 150 peer reviewed journal articles and the textbook Biological Physics of the Developing Embryo, (with Stuart Newman), published by Cambridge University Press.
He holds a PhD in theoretical physics from the Roland Eotvos University, Budapest Hungary. He moved to the United States in the 1980's from the Institute of Physics of the French Atomic Energy Agency in Saclay to accept a professorship at Clarkson University. 
University of Missouri researcher doing groundbreaking work in regenerative medicine. Here is a video:

Science

Organovo strives to advance regenerative medicine to new heights, by enabling bioprinting tissues and 3-D cellular constructs that were not possible before.
The novel and flexible capabilities of the bioprinting technology allow researchers to generate data faster and more efficiently, thus leading to cutting edge scientific findings, publications, and grants.

Organovo's 3-D NovoGen bioprinting technology allows for the placement of cells in any pattern desired.
First, small building blocks of any shape are created from the desired cell type.
Second, these pre-formed cell aggregates are loaded into a print cartridge that is then attached to the bio-printer.
The bioprinter deposits the cell aggregates one layer at a time, creating multiple stacked 2-D patterns.
A non-invasive gel is placed next to the cell aggregates to hold the desired 3-D shape as each layer is placed in 2-D.

After printing, the cell aggregates retain enough cellular mobility for them to flow into one another, creating a fused tissue construct.
The principles of developmental biology, including cellular self-assembly, allow the final construct to mature into the desired shape and properties.

 

World class support for NovoGen MMX

The NovoGen MMX Bioprinter™ is supported by our scientific and engineering team.
Every customer receives bioprinter training and access to Organovo's scaffold-free proprietary bioprinting process, which includes cell preparation to tissue maturation.
Additional consultation and application support are available upon request. Organovo's success comes from enabling our customers' success.  

 

NovoGen MMX Bioprinter

    The NovoGen MMX Bioprinter™ is a novel hardware and software platform at the forefront of bioprinting research and development. The NovoGen MMX™ was developed to meet challenges in biological research.
The platform takes primary or other human cells and shapes them into 3D tissue, with tremendous cellular viability and biology that is superior to even an animal model.
The platform is being used by Organovo's Pharma partners today to enable cutting edge research into drug discovery.

By allowing creation of three dimensional biological structures, Organovo creates functional human tissue that is superior to current disease models.
By enabling printing of tissue in a laboratory environment, investigations on the constructs can be integrated into your current analysis methods.

http://www.invetech.com.au/portfolio/life-sciences/3d-bioprinter-world-first-print-human-tissue/
http://techli.com/2012/07/organovo-bioprinting/#.
https://www.youtube.com/watch?v=1O3c3pUg0L8 (at 28 sec into the video is a full frontal view of the ONVO NovaGen MMX Bioprinter)

SureTrader
ONVO
Current Price
Volume:
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
SureTrader
ONVO News: Organovo Achieves Key Development Milestones for Its Liver Disease and Intestinal Tissue Models 04/16/2018 08:05:00 AM
ONVO News: Cirius Therapeutics' Preclinical Data Demonstrates Potential for Lead Drug Candidate MSDC-0602K in NASH 04/12/2018 08:00:00 AM
ONVO News: Organovo Division Samsara Sciences Announces Multi-Year Supply Agreement With Lonza Bioscience Solutions 03/26/2018 08:05:00 AM
ONVO News: Notice of Effectiveness (effect) 03/26/2018 06:02:12 AM
ONVO News: Post-effective Amendment to Registration Statement (pos Am) 03/16/2018 05:24:00 PM
PlusOneCoin Top Posts
No plusone'd posts yet. Be the first!
PostSubject
#10163   Organovo Jumps 5% Premarket After Reporting Several Breakthroughs RandolRocketman 04/18/18 03:52:26 PM
#10162   SAN DIEGO and KALAMAZOO, Mich., April 12, 2018 RandolRocketman 04/12/18 01:59:58 PM
#10161   Organovo Holdings Presents Data on Modeling Liver Disease RandolRocketman 04/12/18 01:57:32 PM
#10160   Check! bettyfordallstar 04/10/18 05:14:26 PM
#10159   Any chance of an upcoming effort to kick RandolRocketman 04/09/18 01:49:23 PM
#10158   Only reason the stock is up is greed/swing WHP03 03/10/18 09:13:00 PM
#10157   Enigma move underway, perfect chart setup for a Stockcaller 03/09/18 02:02:36 PM
#10156   sold 75 percent of mind at a 80 Oil Man 2 02/22/18 06:05:47 PM
#10155   let the rest of mine go today also----lucky tmonkey 02/22/18 05:09:09 AM
#10154   Looks familiar....... rongreen 02/21/18 11:21:52 PM
#10153   Check out this chart gigl Motba 02/21/18 09:13:08 PM
#10152   I sold out last week, taking a 75% rongreen 02/21/18 03:22:08 PM
#10151   Slow death everyday.... give us a tiny bump Motba 02/21/18 02:00:34 PM
#10150   Don't worry about the increase float it will Oil Man 2 02/21/18 12:45:16 AM
#10149   Approximately 10% increase to the float, if I WHP03 02/09/18 06:33:00 PM
#10148   Qtrly numbers were negative, to factual - down WHP03 02/09/18 06:31:34 PM
#10147   I'll take 24% as lucky. Profit is profit. RandolRocketman 02/09/18 03:35:29 PM
#10146   Good Luck you are going to need it Oil Man 2 02/09/18 11:34:50 AM
#10145   Don't matter what anyone says, I couldn't resist RandolRocketman 02/09/18 10:32:22 AM
#10144   Don't know that, but will try to find rongreen 02/09/18 01:03:21 AM
#10143   Now are those shares existing that were bettyfordallstar 02/09/18 12:16:07 AM
#10142   They will most likely use up the $14.6 rongreen 02/08/18 11:19:17 PM
#10141   Good quarterly numbers, as per conference call, no bettyfordallstar 02/08/18 07:09:40 PM
#10140   If you review my posting I’ve posted here RallyTheMarket 02/02/18 07:11:03 PM
#10139   I am confident we as a society will WHP03 01/29/18 05:46:01 PM
#10138   The move today was happening before the 13G WHP03 01/29/18 05:39:37 PM
#10137   Its been in a downward fall since its wiredawg 01/29/18 04:19:32 PM
#10136   i bt several times last week and am tmonkey 01/29/18 03:43:57 PM
#10135   What baffles me is why the stock is RandolRocketman 01/29/18 03:30:44 PM
#10134   Woohoo, looks like some negative nancies showed up. RandolRocketman 01/29/18 03:26:35 PM
#10133   Agreed, it seems they were capitalizing on the wiredawg 01/29/18 01:46:03 PM
#10132   Avg Buy Out Premium over 10 Yr period WHP03 01/29/18 09:26:35 AM
#10131   It's been my view for a long time WHP03 01/29/18 09:22:50 AM
#10130   seems to be forming a strong bottom finally tmonkey 01/29/18 07:51:40 AM
#10129   agree!!-and i hope they dont low-ball us----tmonkey tmonkey 01/29/18 07:49:54 AM
#10128   What is there to buy here? $4-5MM WHP03 01/29/18 12:17:53 AM
#10127   Would not surprise me if a buyout happened RandolRocketman 01/26/18 01:48:20 PM
#10126   What catalyst is coming up to drive this stockboy 01/26/18 04:44:16 AM
#10125   1/2 hour later rest of 1970 shares filled. stockboy 01/25/18 03:09:20 PM
#10124   930/3k filled stockboy 01/25/18 02:37:56 PM
#10123   Order partial filled 730/3000 will add above 1.40. stockboy 01/25/18 02:35:01 PM
#10120   there was indeed a big buyer sucking up tmonkey 01/24/18 03:25:36 AM
#10119   All in myself...first time in years that I've pupuguru 01/23/18 11:43:33 PM
#10118   doubled down today-turn her loose!!!---tmonkey tmonkey 01/23/18 11:31:45 AM
#10117   took a starter here today---looks pretty beaten down tmonkey 01/22/18 04:02:04 PM
#10116   Total Revenue (TTM) RandolRocketman 01/16/18 12:47:00 PM
#10115   This company certainly has seen better days. Have RallyTheMarket 01/15/18 09:45:23 PM
#10114   More like DILI DILI.....sorry, bad pun pupuguru 12/31/17 10:28:43 AM
#10113   With the volume lately we may see sooner RandolRocketman 12/29/17 11:49:25 PM
#10112   Dilly dilly bettyfordallstar 12/28/17 05:24:50 PM
PostSubject